The Road Ahead: Agentic Omics in 2027 and Beyond
Introduction: Standing at the Inflection Point As we conclude the Agentic Omics series in March 2026, we find ourselves at a genuine inflection point. The past two years have witnessed extraordinary progress: AlphaFold 3’s extension to protein complexes and ligands, the emergence of 7B-parameter genome models like Evo, foundation models for single-cell biology achieving clinical utility, and the first wave of agentic systems orchestrating multi-step scientific workflows. Yet we also face sobering realities: Phase III clinical trial results remain the ultimate arbiter of success, regulatory frameworks are still crystallising, and the gap between computational prediction and biological causality remains stubbornly wide. ...